50% off all subscriptions! ... left. Order NowOrder Now

CytRx Corporation Stock Forecast NASDAQ:CYTR

$0.60 (-0.0167%)

Volume: 25k

Closed: Nov 26, 2021

Hollow Logo Score: 0.071

CytRx Corporation Stock Forecast

$0.60 (-0.0167%)

Volume: 25k

Closed: Nov 26, 2021

Score Hollow Logo 0.071
Which way will CYTR go? Request
Stop-loss: $0.57 (-4.24%)
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 33 and the stock is currently not being overbought or oversold

CytRx Corporation stock upgraded to Hold/Accumulate.
(Updated on Nov 26, 2021)


Hold candidate since 2021-11-26

The CytRx Corporation stock price fell by -0.0167% on the last day (Friday, 26th Nov 2021) from $0.60 to $0.60. and has now fallen 3 days in a row. During the day the stock fluctuated 8.93% from a day low at $0.56 to a day high of $0.61. The price has fallen in 7 of the last 10 days and is down by -24.04% for this period. Volume has increased on the last day by 10 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 25 thousand shares were bought and sold for approximately $15.16 thousand.

The stock is moving within a very wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect CytRx Corporation stock with a 90% probability to be traded between $0.48 and $0.84 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, November 19, 2021, and so far it has risen 3.43%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The CytRx Corporation stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.60 and $0.61. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). CytRx Corporation gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss

CytRx Corporation finds support from accumulated volume at $0.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.0500 between high and low, or 8.93%. For the last week, the stock has had a daily average volatility of 11.74%.

Our recommended stop-loss: $0.57 (-4.24%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from a pivot bottom found 4 days ago.)

Is CytRx Corporation stock A Buy?

CytRx Corporation holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Current score: 0.071

Predicted Opening Price for CytRx Corporation of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$0.59 $0.60 (Overvalued)
Hold/Accumulate Upgraded

Remember To Visit Our YouTube Channel

Volatility and Risk
Daily Average Volatility: 11.74 %
Overall Risk: Very High High Medium Low Very Low
Volatility
11.74 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $0.60
Price: $0.60
Support: $0.58

CYTR Insider Trading Show all Trades

INSIDER POWER

4.290

Last 100 transactions
Buy: 27 992 768 | Sell: 6 525 427 (Shares)
Date Action Amount Person Type
Aug 14, 2020 Buy 150 000 Brien Earl W Common Stock, par value $0.001 per share
Aug 14, 2020 Sell 150 000 Brien Earl W Stock Option (right to buy)
Aug 07, 2020 Buy 450 000 Caldwell Joel K Common Stock, par value $0.001 per share
Aug 07, 2020 Sell 174 627 Caldwell Joel K Common Stock, par value $0.001 per share
Aug 07, 2020 Sell 450 000 Caldwell Joel K Stock Option (right to buy)
Show all Insider Trades
INSIDER POWER

4.290

Last 100 transactions
Buy: 27 992 768 | Sell: 6 525 427 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.64 6.68 %
0.62 3.50 %
0.61 1.53 %
Current price: 0.60
Support 0.57 -4.84 %
0.56 -6.81 %
0.54 -9.99 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.66 10.74 %
0.64 6.35 %
0.60 0.0167 %
Current price 0.60
Support 0.58 -3.32%
0.56 -6.65%
0.55 -8.32%

Click to get the best stock tips daily for free!

About CytRx Corporation

CytRx CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT